IN2011KN04700A - - Google Patents
Download PDFInfo
- Publication number
- IN2011KN04700A IN2011KN04700A IN4700KON2011A IN2011KN04700A IN 2011KN04700 A IN2011KN04700 A IN 2011KN04700A IN 4700KON2011 A IN4700KON2011 A IN 4700KON2011A IN 2011KN04700 A IN2011KN04700 A IN 2011KN04700A
- Authority
- IN
- India
- Prior art keywords
- apcs
- antigen
- assessing
- kits
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- 238000003556 assay Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 229960000074 biopharmaceutical Drugs 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000000412 dendrimer Substances 0.000 abstract 2
- 229920000736 dendritic polymer Polymers 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000011161 development Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 229920000962 poly(amidoamine) Polymers 0.000 abstract 1
- 238000012545 processing Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Manufacturing & Machinery (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immunological responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17961409P | 2009-05-19 | 2009-05-19 | |
| PCT/US2010/035355 WO2010135394A1 (en) | 2009-05-19 | 2010-05-19 | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2011KN04700A true IN2011KN04700A (en) | 2015-07-10 |
Family
ID=43126487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4700KON2011 IN2011KN04700A (en) | 2009-05-19 | 2010-05-19 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120129199A1 (en) |
| EP (2) | EP2432893B1 (en) |
| CN (2) | CN102459629B (en) |
| CA (1) | CA2762586C (en) |
| ES (1) | ES2731343T3 (en) |
| IN (1) | IN2011KN04700A (en) |
| WO (1) | WO2010135394A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488902B (en) * | 2011-11-24 | 2014-06-25 | 清华大学 | Albumin-modified PAMAM self-assembly transgenic composition, preparation method and application thereof |
| EP3563872A1 (en) | 2012-04-05 | 2019-11-06 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| WO2014120804A1 (en) * | 2013-01-30 | 2014-08-07 | University Of Miami | Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof |
| US20140287438A1 (en) * | 2013-03-15 | 2014-09-25 | South Dakota Board Of Regents | Rapid and Inexpensive Assay for Evaluation of Antibody Efficacy with Custom-Designed Fluorescent Nanoparticles |
| EP2972363B1 (en) * | 2013-03-15 | 2019-10-09 | University Of Miami | Immune-potentiating drug nanocarriers |
| US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| KR20250111403A (en) | 2018-03-02 | 2025-07-22 | 엘리시오 테라퓨틱스, 인크. | Cpg amphiphiles and uses thereof |
| JP2022525781A (en) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | Use of amphiphiles in immuno-cell therapy and compositions for them |
| CN110201192B (en) * | 2019-06-05 | 2021-08-31 | 东华大学 | A dendrimer-encapsulated gold nanoparticle probe and its preparation and application |
| CN111172195A (en) * | 2020-02-13 | 2020-05-19 | 翁炳焕 | Preparation method of new coronary pneumonia gene therapy product |
| WO2021215952A1 (en) | 2020-04-24 | 2021-10-28 | Общество С Ограниченной Ответственностью "Индженик" | Method for producing particles of bacteriophages of the genus levivirus |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2409258A1 (en) | 1977-11-21 | 1979-06-15 | Rhone Poulenc Ind | NEW COMPOSITIONS BASED ON AMINOALCOXYAMINES |
| ES2318848T3 (en) * | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | PEPTIDES THAT JOIN PAN DR TO POWER THE IMMUNE RESPONSE. |
| CA2184132C (en) * | 1995-09-21 | 2011-03-15 | Kristina J. Hennessy | An adjuvanted vaccine which is substantially free of non-host albumin |
| US5795582A (en) | 1996-02-07 | 1998-08-18 | Novavax, Inc. | Adjuvant properties of poly (amidoamine) dendrimers |
| US6962790B1 (en) * | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
| AR021849A1 (en) * | 1998-09-30 | 2002-08-07 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE SPECIFIC IMMUNOTHERAPY OF WT1 |
| HK1039749B (en) * | 1998-10-05 | 2007-10-05 | 法麦克萨有限公司 | Use of expressions of ctl and t-helper lymph cells in vaccination |
| US7807377B2 (en) * | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
| US20040241842A1 (en) * | 1999-04-15 | 2004-12-02 | Monash University | Stimulation of thymus for vaccination development |
| AU7404800A (en) | 1999-09-30 | 2001-04-30 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
| US6632435B1 (en) * | 1999-10-20 | 2003-10-14 | City Of Hope | CTL epitope analogs |
| AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| CA2476995A1 (en) * | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| AU2003208314A1 (en) * | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| CN1809379A (en) * | 2003-04-18 | 2006-07-26 | 诺伍德免疫学有限公司 | Disease prevention and vaccination prior to thymic reactivations |
| JP3101496U (en) * | 2003-07-23 | 2004-06-10 | 鴻海精密工業股▲ふん▼有限公司 | Removal tool for connector |
| US7709611B2 (en) * | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
| CN101506266A (en) * | 2005-02-01 | 2009-08-12 | 梅迪沃什有限公司 | Vaccine delivery compositions and methods of use |
| DK2023952T3 (en) * | 2006-05-18 | 2015-10-19 | Epimmune Inc | Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions |
| CN101711360A (en) * | 2007-03-16 | 2010-05-19 | 赛乐思迪斯有限公司 | Cell-mediated immune response assay and kit therefor |
| US9764012B2 (en) * | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
-
2010
- 2010-05-19 IN IN4700KON2011 patent/IN2011KN04700A/en unknown
- 2010-05-19 US US13/321,521 patent/US20120129199A1/en not_active Abandoned
- 2010-05-19 CA CA2762586A patent/CA2762586C/en not_active Expired - Fee Related
- 2010-05-19 ES ES10778304T patent/ES2731343T3/en active Active
- 2010-05-19 EP EP10778304.5A patent/EP2432893B1/en not_active Not-in-force
- 2010-05-19 CN CN201080029414.7A patent/CN102459629B/en not_active Expired - Fee Related
- 2010-05-19 EP EP19171881.6A patent/EP3611270B1/en not_active Not-in-force
- 2010-05-19 WO PCT/US2010/035355 patent/WO2010135394A1/en not_active Ceased
- 2010-05-19 CN CN201910689721.0A patent/CN110542754A/en active Pending
-
2016
- 2016-10-05 US US15/286,131 patent/US20170146526A1/en not_active Abandoned
-
2018
- 2018-12-20 US US16/228,050 patent/US20190170742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170146526A1 (en) | 2017-05-25 |
| EP2432893A4 (en) | 2013-06-19 |
| CN102459629A (en) | 2012-05-16 |
| CA2762586C (en) | 2018-06-19 |
| US20120129199A1 (en) | 2012-05-24 |
| US20190170742A1 (en) | 2019-06-06 |
| CN110542754A (en) | 2019-12-06 |
| CN102459629B (en) | 2019-08-27 |
| CA2762586A1 (en) | 2010-11-25 |
| EP3611270B1 (en) | 2021-12-01 |
| ES2731343T3 (en) | 2019-11-15 |
| EP2432893B1 (en) | 2019-05-01 |
| EP3611270A1 (en) | 2020-02-19 |
| WO2010135394A1 (en) | 2010-11-25 |
| EP2432893A1 (en) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2011KN04700A (en) | ||
| EP2413964A4 (en) | VACCINATE COMPOSITIONS AND METHOD FOR THEIR USE | |
| Sheppard et al. | Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens | |
| EA201892021A1 (en) | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE OF CANCER DISEASES IN IMMUNOTHERAPY | |
| EA201891759A1 (en) | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE OF CANCER DISEASES IN IMMUNOTHERAPY | |
| JP2014523406A5 (en) | ||
| Fratzke et al. | Subunit vaccines using TLR triagonist combination adjuvants provide protection against Coxiella burnetii while minimizing reactogenic responses | |
| Cho et al. | Design of immunogenic and effective multi-epitope DNA vaccines for melanoma | |
| Iwama et al. | Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice | |
| WO2022013609A1 (en) | Sars-cov-2 vaccine compositions and methods of preparation and use | |
| McElhaney | Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response | |
| Jan et al. | Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge | |
| Woodworth et al. | MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates | |
| DK2066341T3 (en) | PROCEDURE FOR INITIATING OR INDUCING AN IMMUNE RESPONSE | |
| Chang et al. | A novel vaccine adjuvant for recombinant flu antigens | |
| AU2023202175A1 (en) | Self-assembling peptide scaffold | |
| Thueng-in et al. | Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines | |
| Buaklin et al. | Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein | |
| Rahman | Metabolomics for Personalized Vaccinology | |
| Zimmerman et al. | Lessons from next generation influenza vaccines for inflammatory disease therapies | |
| Li et al. | PRR adjuvants restrain high stability peptides presentation on APCs | |
| US20220023412A1 (en) | Compositions Useful in Both Homologous And Heterologous Vaccine Regimens | |
| Jan | Vaccine-induced adaptive T cell immunity enhances protective responses against Coxiella burnetii | |
| CN105530957A (en) | CpG oligodeoxynucleotide, immune composition comprising same, and method for preparing composition and stimulating immune response through same | |
| Lemmon et al. | KITS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS |